Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

17-12-2020 | SABCS 2020 | Conference coverage | Video

Updated findings on low-risk MINDACT participants reported

Laura van 't Veer discusses the latest data from the MINDACT trial of adjuvant chemotherapy de-escalation in hormone receptor-positive early breast cancer and puts the results in the context of the RxPONDER and TAILORx findings.

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript
Image Credits